Funded Biotechnology Startups in Cambridge
Among the 50 biotechnology rounds listed for Cambridge, the largest disclosed amount is Praxis Precision Medicines at $575M (2026-01-06) and it sits near t…
Among the 50 biotechnology rounds listed for Cambridge, the largest disclosed amount is Praxis Precision Medicines at $575M (2026-01-06) and it sits near the top end of a small group of very large rounds such as Kymera Therapeutics $602M (2025-12-10) and Tango Therapeutics $600M (2026-06-09). Outside that upper band, many disclosed rounds are clustered in the tens of millions—for example $4M to $55M appears frequently, with smaller-ticket rounds like Genflow Biosciences at $1M (2026-03-05) and Lysoway Therapeutics at $3M (2026-06-01) acting as low outliers.
Geographically, the list splits between Cambridge, Massachusetts (e.g., Flare Therapeutics $85M on 2026-06-30; City Therapeutics $100M on 2026-06-08) and Cambridge, Cambridgeshire, United Kingdom (e.g., CellCentric $220M on 2026-05-06; bit.bio $50M on 2026-01-09). Temporally, the most recent entry is Flare Therapeutics on 2026-06-30, while the rows span back to 2025-12-10, with multiple high-ticket financings concentrated in late December 2025 and the June 2026 window.
Most recent rounds
50 of 239189 more funded startups
This page shows the 50 most recent rounds (back to Dec 2025). The full 239-company history for this listing is available on a paid plan.
Unlock all 239 companies in this listing — full funding history, investors, and founders.
Related listings
Frequently asked
Which disclosed rounds stand out most as outliers in size, and how extreme is the top end versus the rest?
The largest disclosed amount is Praxis Precision Medicines at $575M (2026-01-06), with Kymera Therapeutics at $602M (2025-12-10) and Tango Therapeutics at $600M (2026-06-09) in the same high band. At the low end, Genflow Biosciences is disclosed at $1M (2026-03-05), and several other small rounds sit around $3M–$5M (e.g., Lysoway Therapeutics $3M on 2026-06-01; Deck Bio $3M on 2026-04-09).
Is the list concentrated in one geography (Cambridge, MA vs Cambridge, UK), and do the biggest rounds cluster accordingly?
The geography is split across Cambridge, Massachusetts and Cambridge, Cambridgeshire (UK), rather than a single hub. The very largest disclosed rounds include both sides—for example Tango Therapeutics $600M (Cambridge, MA) on 2026-06-09, and CellCentric $220M (Cambridge, UK) on 2026-05-06—suggesting the upper tail is not confined to just one Cambridge.
How much activity is packed into the most recent window shown on the page?
The most recent date in the dataset is 2026-06-30 (Flare Therapeutics $85M). A noticeable cluster also runs through June 2026 with multiple entries in mid-to-late June (e.g., Dyne Therapeutics $200M on 2026-06-17; Parabilis Medicines $75M on 2026-06-11; Tango Therapeutics $600M on 2026-06-09).
What stage-label pattern dominates, and are “Series Unknown” rounds a majority?
“Series Unknown” appears frequently: it is used for entries such as Flare Therapeutics (Series C is not unknown, but many others are), including Parabilis Medicines $75M (2026-06-11), Relay Therapeutics $275M (2026-05-20), and Intellia Therapeutics $180M (2026-04-29). “undisclosed” amounts show up as well (e.g., Harness Therapeutics on 2026-06-09; Tevard Biosciences on 2026-05-20; Kytopen on 2026-04-07), indicating that even when geography is specified, deal size visibility can be incomplete.
Which disclosed rounds sit in the low-ticket band (single-digit to small millions), and do they appear across both geographies?
Several disclosed amounts are in the single-digit millions or low-single digits across the list, such as Genflow Biosciences $1M (2026-03-05) and Casma Therapeutics $8M (2026-03-10), plus Seed rounds like STRM.BIO $8M (2026-01-07) and Sparxell $5M (2026-02-03). These low-disclosure amounts are not limited to one Cambridge: Cambridge, MA entries include Genflow Biosciences, while Cambridge, UK entries include Sparxell and Semarion $4M (2026-03-31).
Where do the date extremes land, and what does that imply about timing of big financings?
The earliest row shown is 2025-12-10, with Kymera Therapeutics disclosed at $602M (2025-12-10), while the latest is 2026-06-30 with Flare Therapeutics at $85M. The presence of a top-end financing right at the earliest date (Kymera $602M) and another top-end financing later in the June window (Tango $600M on 2026-06-09) suggests large rounds occur at both temporal edges rather than only in the middle of the span.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.